Revue Neurologique (REV NEUROL-FRANCE)

Publisher: Société Française de Neurologie, Elsevier Masson

Journal description

Au service de l'actualité neurologique. La Revue Neurologique publie des mises au point, des mémoires originaux, des brèves communications, des lettres de l'Editeur... en neurologie, neurochirurgie, neurophysiologie, neuropathologie, neurologie expérimentale et autres disciplines associées. Tribune des équipes francophones et internationales. Organe de diffusion de la recherche francophone et internationale, elle publie des articles scientifiques qui vous permettent de vous tenir informé des grandes acquisitions en neurologie clinique et en neurosciences. Un renouveau éditorial. Soucieuse de maintenir sa place parmi les différents outils de travail des neurologues, la Revue Neurologique maintient une ligne éditoriale de qualité pour répondre aux exigences de ses lecteurs. Soutenue par un Comité Editorial chargé de susciter la soumission d'articles d'équipes de premier rang, la rédaction a mis au point une partie de formation post-universitaire avec un grand nombre de rubriques tres variées

Current impact factor: 0.66

Impact Factor Rankings

2016 Impact Factor Available summer 2017
2014 / 2015 Impact Factor 0.663
2013 Impact Factor 0.601
2012 Impact Factor 0.51
2011 Impact Factor 0.488
2010 Impact Factor 0.528
2009 Impact Factor 0.605
2008 Impact Factor 0.508
2007 Impact Factor 0.448
2006 Impact Factor 0.501
2005 Impact Factor 0.443
2004 Impact Factor 0.434
2003 Impact Factor 0.456
2002 Impact Factor 0.468
2001 Impact Factor 0.598
2000 Impact Factor 0.692
1999 Impact Factor 1.013
1998 Impact Factor 1.45
1997 Impact Factor 1.11

Impact factor over time

Impact factor

Additional details

5-year impact 0.50
Cited half-life >10.0
Immediacy index 0.17
Eigenfactor 0.00
Article influence 0.14
Website Revue Neurologique website
ISSN 0035-3787
OCLC 163811705
Material type Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Elsevier Masson

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Authors pre-print on any website, including arXiv and RePEC
    • Author's post-print on author's personal website immediately
    • Author's post-print on open access repository after an embargo period of between 12 months and 48 months
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months
    • Author's post-print may be used to update arXiv and RepEC
    • Publisher's version/PDF cannot be used
    • Must link to publisher version with DOI
    • Author's post-print must be released with a Creative Commons Attribution Non-Commercial No Derivatives License
    • Publisher last reviewed on 01/05/2015
    • 'Elsevier Masson' is an imprint of 'Elsevier'
  • Classification

Publications in this journal

  • No preview · Article · Jan 2016 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: Epilepsy is a burden affecting no fewer than 50 million patients worldwide. It is a heterogeneous group of disorders comprising both common and very rare forms, thus rendering its epidemiological investigations rather difficult. Moreover, making an epilepsy diagnosis per se can be challenging due to an evolving system of classification, and its dependency on local habits and culture. Any attempt at meta-analyses must consider such biases when pooling data from different centers and countries. Differentiating a contextual seizure from chronic epilepsy is every epileptologist's daily mission, yet it is also crucial for achieving a proper estimation of the epidemiology of epilepsy. Our present objective was to provide an overview of the epidemiology of both syndromic and non-syndromic epilepsy. Most epileptic syndromes tend to be rare and, thus, the feasibility of epidemiological quantification in populations is also addressed. Regarding its prevalence and cost, epilepsy deserves greater attention than it generally receives, as it appears to continue to be a condition under persistent taboos.
    No preview · Article · Jan 2016 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: France is a country for which the epidemiology of migraine is very well known. Based on the results of the main studies over the last 20 years, this brief review presents the key descriptive data for French migraine epidemiology, and considers its prevalence, individual impact, recognition and medical management, and social impact.
    No preview · Article · Dec 2015 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple sclerosis (MS) is the most frequently seen demyelinating disease, with a prevalence that varies considerably, from high levels in North America and Europe (>100/100,000 inhabitants) to low rates in Eastern Asia and sub-Saharan Africa (2/100,000 population). Knowledge of the geographical distribution of the disease and its survival data, and a better understanding of the natural history of the disease, have improved our understanding of the respective roles of endogenous and exogenous causes of MS. Concerning mortality, in a large French cohort of 27,603 patients, there was no difference between MS patients and controls in the first 20 years of the disease, although life expectancy was reduced by 6-7 years in MS patients. In 2004, the prevalence of MS in France was 94.7/100,000 population, according to data from the French National Health Insurance Agency for Salaried Workers (Caisse nationale d'assurance maladie des travailleurs Salariés [CNAM-TS]), which insures 87% of the French population. This prevalence was higher in the North and East of France. In several countries, including France, the gender ratio for MS incidence (women/men) went from 2/1 to 3/1 from the 1950s to the 2000s, but only for the relapsing-remitting form. As for risk factors of MS, the most pertinent environmental factors are infection with Epstein-Barr virus (EBV), especially if it arises after childhood and is symptomatic. The role of smoking in MS risk has been confirmed, but is modest. In contrast, vaccines, stress, traumatic events and allergies have not been identified as risk factors, while the involvement of vitamin D has yet to be confirmed. From a genetic point of view, the association between HLA-DRB1*15:01 and a high risk of MS has been known for decades. More recently, immunogenetic markers have been identified (IL2RA, IL7RA) and, in particular thanks to studies of genome-wide associations, more than 100 genetic variants have been reported. Most of these are involved in the immune response and often associated with other autoimmune diseases. Studies of the natural history of MS suggest it is a two-phase disease: in the first phase, inflammation is focal with flares; and in the second phase, disability progresses independently of focal inflammation. This has clear implications for therapy. Age may also be a key factor in the phenotype of the disease. In conclusion, France is a high-risk country for MS, but it only slightly reduces life expectancy. MS is a multifactorial disease and the implications of immunogenetics are major. Preventative approaches might be derived from knowledge of the risk factors and natural history of the disease (smoking, vitamin D).
    No preview · Article · Dec 2015 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although comparisons are difficult due to differences in methodologies, the annual incidence rates of central nervous system (CNS) tumors range from 8.5 to 21.4/100,000 population according to cancer registries, with a predominance of neuroepithelial tumors in men and meningiomas in women. An increase in the incidence of CNS tumors has been observed during the past decades in several countries. It has been suggested that this trend could be due to aging of the population, and improvements in diagnostic imaging and healthcare access, but these factors do not explain differences in incidence by gender and histological subtypes. Several etiological hypotheses related to intrinsic (sociodemographic, anthropometric, hormonal, immunological, genetic) and exogenous (ionizing radiation, electromagnetic fields, diet, infections, pesticides, drugs) risk factors have led to analytical epidemiological studies to establish relationships with CNS tumors. The only established environmental risk factor for CNS tumors is ionizing radiation exposure. However, for other risk factors, studies have been inconsistent and inconclusive due to systematic differences in study design and difficulties in accurately measuring exposures. Thus, the etiology of CNS tumors is complex and may involve several genetic and/or environmental factors that may act differently according to histological subtype.
    No preview · Article · Dec 2015 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of motor neurons, resulting in worsening weakness of voluntary muscles until death occurs from respiratory failure. The incidence of ALS in European populations is two to three people per year per 100,000 of the general population. In Europe, crude prevalences range from 1.1/100,000 population in Yugoslavia to 8.2/100,000 in the Faroe Islands. Major advances have been made in our understanding of the genetic causes of ALS, whereas the contribution of environmental factors has been more difficult to assess and large-scale studies have not yet revealed a replicable, definitive environmental risk factor. The only established risk factors to date are older age, male gender and a family history of ALS. Median survival time from onset to death is usually 3 years from the first appearance of symptoms. Older age and bulbar onset are consistently reported to have poorer outcomes. However, there are conflicting data regarding gender, diagnostic delay and El Escorial criteria. The rate of symptom progression has been revealed to be an independent prognostic factor. Psychosocial factors and impaired cognitive function are negatively related to ALS outcome, while nutritional status and respiratory function are also related to ALS prognosis. The effect of enteral nutrition on survival is still unclear, although noninvasive positive pressure ventilation (NIPPV) has been found to improve survival. These findings have relevant implications for the design of future trials.
    No preview · Article · Dec 2015 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: Because of the growing size and aging of the world's population, the global burden of stroke is increasing dramatically. Current epidemiological data indicate that 16.9million people suffer a stroke each year, which represents a global incidence of 258/100,000/year, with marked differences between high- and low-income countries, and an age-adjusted incidence 1.5 times higher in men than in women. Although primary prevention has contributed to a decrease in stroke incidence in high-income countries, the so-called 'epidemiological transition' has led to an increase in incidence in middle-to-low-income countries as well. In addition, the incidence of ischemic stroke in young adults is on the rise, suggesting a need for specific preventative interventions in that age group. The number of stroke survivors almost doubled between 1990 and 2010, and has now reached 33 million people. According to epidemiological projections, this number will rise to 77 million by 2030. In France, the number of hospitalizations for an acute cerebrovascular event was about 138,000 in 2009, accounting for 3% of the total national health expenditure. Outcomes after stroke are frequently impaired by complications, including motor handicaps, dementia, depression, fatigue, and a high risk of early rehospitalization and institutionalization, with adverse consequences in terms of socioeconomic costs. In addition, there are 5.9 million stroke-related deaths worldwide every year. Finally, although many analytical epidemiological studies have considerably increased our knowledge of risk factors for stroke, the recent INTERSTROKE study provided evidence that 10 risk factors alone accounted for 88% of all strokes. Many of these risk factors are modifiable, which suggests that efforts should be made to promote interventions that aim to reduce the risk of stroke. A new 'mass approach' aiming to reduce the level of stroke risk factors in all people in a region, regardless of any given individual's level of risk, is currently still being developed. This interesting and innovative way to spread stroke awareness is based on the use of an internationally validated mobile-phone application that can calculate the risk of stroke for any given individual, and also contains a section to educate people on stroke warning symptoms and signs.
    No preview · Article · Dec 2015 · Revue Neurologique

  • No preview · Article · Nov 2015 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: New therapeutic strategies are under evaluation to improve the treatment of acute ischemic stroke (AIS). Approaches combining intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) and antithrombotic agents are currently evaluated. The combination of IV rt-PA and aspirin showed a high rate of intracranial hemorrhage whereas the association of rt-PA and eptifibatide seems more promising. The results of recent studies evaluating the administration of eptifibatide or argatroban in conjunction with conventional IV thrombolysis with rt-PA are expected to clarify the safety and efficacy of these treatments. More fibrin-specific plasminogen activators, tenecteplase and desmoteplase, are also investigated. These fibrinolytic agents showed a favorable safety profile but their efficacy in AIS remains uncertain. While phase III studies, DIAS-3 and DIAS-4, evaluating IV desmoteplase up to nine hours after stroke onset did not meet the primary endpoint, the results of studies comparing IV tenecteplase and IV rt-PA are expected.
    No preview · Article · Nov 2015 · Revue Neurologique

  • No preview · Article · Nov 2015 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: La maladie de Parkinson (MP) est une affection neurodégénérative fréquente et complexe, dont l’incidence augmente avec l’âge. Bien que la MP ait été définie historiquement par une perte progressive des neurones dopaminergiques de la substance noire, sa physiopathologie comporte également un dysfonctionnement d’autres neurotransmetteurs et d’autres structures cérébrales que les noyaux gris centraux. La présentation clinique de la MP chez le sujet âgé est différente de celle de sujets plus jeunes, avec une progression plus rapide, une moindre fréquence du tremblement, des signes axiaux plus marqués, une plus grande fréquence de signes non moteurs liés à l’atteinte concomitante des systèmes non dopaminergiques, et enfin une plus grande fréquence de lésions associées. Malgré sa forte prévalence de la MP chez le sujet âgé, peu d’études thérapeutiques ont été menées dans une population gériatrique. Il convient néanmoins de connaître les grands principes d’une prise en charge optimisée, multidisciplinaire, visant à améliorer la gêne fonctionnelle tout en s’assurant d’une bonne tolérance médicamenteuse. L’objectif de cette revue est de faire une mise au point sur les particularités cliniques et thérapeutiques de la MP en gériatrie.
    No preview · Article · Nov 2015 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: L’accumulation d’une protéine spécifique sous forme agrégée est un phénomène commun aux maladies neurodégénératives humaines. Dans la maladie de Parkinson, cette protéine est l’α-synucléine qui est une protéine neuronale de 143 acides aminés. De conformation monomérique en solution, elle possède également une capacité naturelle à s’agréger en structures amyloïdes (dimères, oligomères, fibrilles puis corps ou neurites de Lewy). Elle détient donc les caractéristiques d’une protéine prion (différentes conformations, initiation et dissémination d’un processus transconformationnel). De nombreux arguments expérimentaux in vitro et in vivo sur des animaux transgéniques ou sauvages sont en faveur d’une progression prion-like de la maladie de Parkinson. La diffusion séquentielle et prédictive de l’α-synucléine mise en évidence par Braak et al. et sa corrélation avec les signes non moteurs vont tout à fait dans le sens de cette progression prion-like. Même si le facteur déclenchant à l’origine du mauvais repliement et de l’agrégation de la protéine cible reste inconnu, la maladie de Parkinson est un modèle très pertinent pour l’étude de ces mécanismes et aussi pour tester des traitements spécifiques ciblant les assemblages d’α-synucléine et leur propagation dès la phase pré-motrice de la maladie. Malgré cette progression prion-like, il n’existe actuellement aucun argument indiquant un risque de transmission interhumaine de la maladie de Parkinson.
    No preview · Article · Nov 2015 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: L’encéphalomyélite aiguë disséminée (ADEM) est une affection inflammatoire démyélinisante du système nerveux central (SNC) médiée par un mécanisme auto-immun. Les caractéristiques de cette affection en Tunisie sont encore peu connues.
    No preview · Article · Nov 2015 · Revue Neurologique
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nous rapportons le cas d’une angiopathie amyloïde cérébrale inflammatoire (AAC), ayant présenté un déclin cognitif rapide, des crises d’épilepsie, des hallucinations visuelles, une hyperprotéinorrachie et une leucopathie hémisphérique droite. La biopsie cérébrale a permis de poser le diagnostic d’AAC. Bien qu’aucun infiltrat inflammatoire n’ait été retrouvé sur le prélèvement biopsié, la corticothérapie a permis une régression des lésions radiologiques mais sans amélioration clinique notable. L’angiopathie amyloïde cérébrale inflammatoire est une pathologie rare, définie par des lésions d’angiopathie amyloïde cérébrale classique et un infiltrat périvasculaire au contact des vaisseaux atteints. Dans les cas de démence rapidement progressive associée à une leucopathie, il faut savoir évoquer ce diagnostic : l’amélioration des troubles cognitifs étant possible après instauration de traitement immunosuppresseur.
    No preview · Article · Nov 2015 · Revue Neurologique

  • No preview · Article · Nov 2015 · Revue Neurologique